170 related articles for article (PubMed ID: 22886631)
1. Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents.
Khamis ZI; Iczkowski KA; Sang QX
Med Res Rev; 2012 Sep; 32(5):1026-77. PubMed ID: 22886631
[TBL] [Abstract][Full Text] [Related]
2. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
Man YG; Gardner WA
Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
[TBL] [Abstract][Full Text] [Related]
3. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
5. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
Chua CW; Chiu YT; Yuen HF; Chan KW; Man K; Wang X; Ling MT; Wong YC
Clin Cancer Res; 2009 Jul; 15(13):4322-35. PubMed ID: 19509141
[TBL] [Abstract][Full Text] [Related]
6. A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival.
Bacac M; Provero P; Mayran N; Stehle JC; Fusco C; Stamenkovic I
PLoS One; 2006 Dec; 1(1):e32. PubMed ID: 17183660
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis.
Henrique R; Jerónimo C; Teixeira MR; Hoque MO; Carvalho AL; Pais I; Ribeiro FR; Oliveira J; Lopes C; Sidransky D
Mol Cancer Res; 2006 Jan; 4(1):1-8. PubMed ID: 16446401
[TBL] [Abstract][Full Text] [Related]
8. Molecular markers and determinants of prostate cancer metastasis.
Gopalkrishnan RV; Kang DC; Fisher PB
J Cell Physiol; 2001 Dec; 189(3):245-56. PubMed ID: 11748582
[TBL] [Abstract][Full Text] [Related]
9. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
10. Amphiregulin expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 93 cases.
Bostwick DG; Qian J; Maihle NJ
Prostate; 2004 Feb; 58(2):164-8. PubMed ID: 14716741
[TBL] [Abstract][Full Text] [Related]
11. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
Zeng L; Kyprianou N
Prostate Cancer Prostatic Dis; 2005; 8(1):7-13. PubMed ID: 15477876
[TBL] [Abstract][Full Text] [Related]
12. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
13. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations.
Shibata MA; Ward JM; Devor DE; Liu ML; Green JE
Cancer Res; 1996 Nov; 56(21):4894-903. PubMed ID: 8895741
[TBL] [Abstract][Full Text] [Related]
14. Integrative analysis of genomic aberrations associated with prostate cancer progression.
Kim JH; Dhanasekaran SM; Mehra R; Tomlins SA; Gu W; Yu J; Kumar-Sinha C; Cao X; Dash A; Wang L; Ghosh D; Shedden K; Montie JE; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
Cancer Res; 2007 Sep; 67(17):8229-39. PubMed ID: 17804737
[TBL] [Abstract][Full Text] [Related]
15. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues.
Häggman MJ; Macoska JA; Wojno KJ; Oesterling JE
J Urol; 1997 Jul; 158(1):12-22. PubMed ID: 9186314
[TBL] [Abstract][Full Text] [Related]
16. High-grade prostate intraepithelial neoplasia shares cytogenetic alterations with invasive prostate cancer.
Alcaraz A; Barranco MA; Corral JM; Ribal MJ; Carrió A; Mallofré C; Llopis J; Cetina A; Alvarez-Vijande R
Prostate; 2001 Apr; 47(1):29-35. PubMed ID: 11304727
[TBL] [Abstract][Full Text] [Related]
17. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
18. In situ and intraductal epithelial proliferations of prostate: definitions and treatment implications. Part 1: Prostatic intraepithelial neoplasia.
Clouston D; Bolton D
BJU Int; 2012 Apr; 109 Suppl 3():22-6. PubMed ID: 22458488
[TBL] [Abstract][Full Text] [Related]
19. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.
Kasper S
J Cell Biochem; 2005 Feb; 94(2):279-97. PubMed ID: 15565647
[TBL] [Abstract][Full Text] [Related]
20. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
Luchman HA; Benediktsson H; Villemaire ML; Peterson AC; Jirik FR
PLoS One; 2008; 3(12):e3940. PubMed ID: 19081794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
